Idiopathic Pulmonary Fibrosis (IPF)
Patient Condition
The patient sought medical treatment due to shortness of breath and dry cough after exercise, and had a history of smoking (15 pack years). HRCT showed grid shadows and honeycomb changes in both lower lungs. Lung function: FVC 64% predicted, DLCO 50% predicted. 6MWD 360m, mMRC score 2. Diagnosis of IPF.
Treatment Timeline
| Phase | Details | Date |
|---|---|---|
| diagnosis | ||
| treatment initiation | ||
| Standardized treatment (months 1-12) | ||
| Maintenance treatment (Months 13-18) |
Treatment Outcome
| before | FVC accounted for 64% of predicted value, DLCO accounted for 50% of predicted value, 6MWD 360m, mMRC score 2 |
|---|---|
| after | After 18 months of treatment, FVC accounted for 61% of the predicted value (annual decline rate of approximately 2%), DLCO accounted for 47% of the predicted value, 6MWD 375m, and mMRC score 2 |
| highlight | Pirfenidone treatment for 18 months effectively delays the progression of IPF. Domestic pirfenidone is cost-effective and has a relatively light financial burden on patients. |